


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A compound of Formula I



wherein:

R¹ is C₆H₅CH₂OCH₂-, C₆H₅(CH₂)₃- or indol-3-ylmethyl;
Y is pyrroolidinyl pyrrolidinyl, 4-methyl-piperidinyl or NR²R²;
R² are each independently a C₁ to C₆ alkyl C₁-C₆ alkyl;
R³ is 2-naphthyl or phenyl para-substituted by W;
W is H, F, CF₃, C₁-C₆ alkoxy or phenyl; and
R⁴ is H or CH₃;

or a pharmaceutically acceptable salt or solvate thereof.

Claim 2 (canceled).

Claim 3 (currently amended): A compound of Claim 1 wherein said compound has the (R,R) stereoconfiguration.

Claim 4 (original): A method for increasing the level of endogenous growth hormone in a human or an animal which comprises administering to said human or an animal which comprises administering to said human or animal an effective amount of a compound of Claim 1.

Claim 5 (original): A method for the treatment or prevention of a physiological condition which may be modulated by an increase in endogenous growth hormone which comprises administering to an animal in need of said treatment an effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt or solvate thereof.

Claim 6 (original): A pharmaceutical formulation which comprises, as an active ingredient a compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, associated with one or more pharmaceutically acceptable carriers, diluents, or excipients.

Claim 7 (original): A pharmaceutical formulation according to Claim 6 which further comprises a bone-antiresorptive agent.

Claim 8 (currently amended): A method according to Claim 7 5 which further comprises administering to a patient a bone-antiresorptive agent.

Claim 9 (original): A method according to Claim 8 wherein said bone-antiresorptive agent is a bisphosphonate.

Claim 10 (new): A compound of Claim 1 wherein R¹ is C₆H₅(CH₂)₃- and Y is pyrrolidin-1-yl; or a pharmaceutically acceptable salt or solvate thereof.

Claim 11 (new): A compound of Claim 1 wherein R¹ is C₆H₅CH₂OCH₂- and Y is pyrrolidin-1-yl; or a pharmaceutically acceptable salt or solvate thereof.

Claim 12 (new): A compound of Claim 1 wherein R¹ is C₆H₅(CH₂)₃- and Y is 4-methylpiperidin-1-yl; or a pharmaceutically acceptable salt or solvate thereof.

Claim 13 (new): A pharmaceutical formulation which comprises, as an active ingredient a compound of Claim 10, or a pharmaceutically acceptable salt or solvate thereof, associated with one or more pharmaceutically acceptable carriers, diluents, or excipients.

Claim 14 (new): A pharmaceutical formulation according to Claim 13 which further comprises a bone-antiresorptive agent.

Claim 15 (new): A method for the treatment or prevention of a physiological condition which may be modulated by an increase in endogenous growth

Serial No. 09/890,163

hormone which comprises administering to an animal in need of said treatment an effective amount of a compound of Claim 10 or a pharmaceutically acceptable salt or solvate thereof.